NASDAQ:KRYS Krystal Biotech (KRYS) Stock Price, News & Analysis $339.75 -2.00 (-0.59%) As of 11:06 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Krystal Biotech Stock (NASDAQ:KRYS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Krystal Biotech alerts:Sign Up Key Stats Today's Range$337.92▼$343.9550-Day Range$312.57▼$371.4752-Week Range$158.08▼$382.54Volume25,135 shsAverage Volume331,583 shsMarket Capitalization$10.06 billionP/E Ratio42.57Dividend YieldN/APrice Target$377.20Consensus RatingModerate Buy Company Overview Krystal Biotech, Inc. is a biotechnology company focused on developing and commercializing genetic medicines for rare diseases. The company uses engineered herpes simplex virus type 1 (HSV-1) vectors to deliver functional genes to targeted tissues, with an emphasis on treatments that can be administered directly to affected areas. Krystal Biotech’s lead product is Vyjuvek (beremagene geperpavec-svdt), a topical gene therapy for wounds associated with dystrophic epidermolysis bullosa, a rare inherited disorder that causes fragile skin and recurrent blistering. Vyjuvek was approved by the U.S. Food and Drug Administration in 2023 and is marketed in the United States. Founded in 2015 and headquartered in Pittsburgh, Pennsylvania, Krystal Biotech is also developing additional gene therapy candidates for rare dermatological, pulmonary and other genetic diseases. Its pipeline has included programs such as KB407 for cystic fibrosis and KB408 for alpha-1 antitrypsin deficiency. The company is led by President and Chief Executive Officer Krish S. Krishnan, who co-founded Krystal Biotech with Suma Krishnan.AI Generated. May Contain Errors. Read More Krystal Biotech Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks71st Percentile Overall ScoreKRYS MarketRank™: Krystal Biotech scored higher than 71% of companies evaluated by MarketBeat, and ranked 251st out of 901 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.3 / 5Analyst RatingModerate Buy Consensus RatingKrystal Biotech has received a consensus rating of Moderate Buy. The company's average rating score is 2.92, and is based on 1 strong buy rating, 10 buy ratings, 2 hold ratings, and no sell ratings.Upside PotentialKrystal Biotech has a consensus price target of $377.20, representing about 10.4% upside from its current price of $341.75.Amount of Analyst CoverageKrystal Biotech has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Krystal Biotech's stock forecast and price target. Earnings and Valuation2.5 / 5Proj. Earnings Growth22.46% Earnings GrowthEarnings for Krystal Biotech are expected to grow by 22.46% in the coming year, from $7.48 to $9.16 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Krystal Biotech is 42.83, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 38.99.Price to Earnings Ratio vs. SectorThe P/E ratio of Krystal Biotech is 42.83, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 274.10.Price to Book Value per Share RatioKrystal Biotech has a P/B Ratio of 8.13. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Krystal Biotech's valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted13.02% of the float of Krystal Biotech has been sold short.Short Interest Ratio / Days to CoverKrystal Biotech has a short interest ratio ("days to cover") of 15.27, which indicates bearish sentiment.Change versus previous monthShort interest in Krystal Biotech has recently increased by 4.46%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldKrystal Biotech does not currently pay a dividend.Dividend GrowthKrystal Biotech does not have a long track record of dividend growth. News and Social Media4.5 / 5News Sentiment1.27 News SentimentKrystal Biotech has a news sentiment score of 1.27. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.49 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Krystal Biotech this week, compared to 5 articles on an average week.Search Interest6 people have searched for KRYS on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.MarketBeat Follows8 people have added Krystal Biotech to their MarketBeat watchlist in the last 30 days. Company Ownership1.9 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Krystal Biotech insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $17,558,270.00 in company stock.Percentage Held by Insiders13.10% of the stock of Krystal Biotech is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions86.29% of the stock of Krystal Biotech is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Krystal Biotech's insider trading history. Receive KRYS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Krystal Biotech and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. KRYS Stock News HeadlinesBank of America Forecasts Strong Price Appreciation for Krystal Biotech (NASDAQ:KRYS) StockSeptember 23 at 1:30 AM | americanbankingnews.comBofA Adjusts Price Target on Krystal Biotech to $400 From $392, Keeps Buy RatingSeptember 21 at 11:55 PM | marketscreener.comMElon gets it. Do you?Moderna's stock jumped nearly 200% in a single day after a successful Phase 3 trial for its cancer drug, and Merck added $43 billion to its market cap on the same news. Porter & Co. says AI-driven drug discovery and automated labs are cutting development timelines by up to 80% and lifting early clinical success rates to 90%, fueling what they call biotech's Ignition Point.September 24 at 1:00 AM | Porter & Company (Ad)Suma Krishnan Sells 25,000 Shares of Krystal Biotech (NASDAQ:KRYS) StockSeptember 5, 2026 | insidertrades.comKrystal Biotech to Participate in 2026 Cantor Global Healthcare ConferenceSeptember 3, 2026 | quiverquant.comQKrystal Biotech to Present at 2026 Cantor Global Healthcare ConferenceSeptember 3, 2026 | globenewswire.comKrystal Biotech (KRYS) Has a New Rating from RBC CapitalAugust 17, 2026 | theglobeandmail.comHere are Friday’s top Wall Street analyst research calls: Cinemark, Digital Realty, Fox Corporation, Krystal Biotech, LTC Properties, Roku, SanDisk, T-Mobile US, Wayfair, and ...August 14, 2026 | msn.comSee More Headlines KRYS Stock Analysis - Frequently Asked Questions How have KRYS shares performed this year? Krystal Biotech's stock was trading at $246.54 at the start of the year. Since then, KRYS stock has increased by 38.6% and is now trading at $341.75. How were Krystal Biotech's earnings last quarter? Krystal Biotech, Inc. (NASDAQ:KRYS) issued its quarterly earnings results on Monday, August, 3rd. The company reported $1.79 earnings per share for the quarter, topping the consensus estimate of $1.70 by $0.09. The firm had revenue of $119.22 million for the quarter, compared to analyst estimates of $120.93 million. Krystal Biotech had a net margin of 54.82% and a trailing twelve-month return on equity of 19.34%. Read the conference call transcript. When did Krystal Biotech IPO? Krystal Biotech (KRYS) raised $40 million in an IPO on Wednesday, September 20th 2017. The company issued 3,960,000 shares at a price of $9.00-$11.00 per share. Ladenburg Thalmann acted as the underwriter for the IPO. Who are Krystal Biotech's major shareholders? Krystal Biotech's top institutional investors include BlackRock Inc. (14.13%), William Blair Investment Management LLC (1.93%), Jupiter Topco LLC (0.87%) and Bank of America Corp DE (0.87%). Insiders that own company stock include Suma Krishnan, Daniel Janney, Dino A Rossi, Kathryn Romano, John Charles Thomas and Julian S Gangolli. View institutional ownership trends. How do I buy shares of Krystal Biotech? Shares of KRYS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Krystal Biotech own? Based on aggregate information from My MarketBeat watchlists, some other companies that Krystal Biotech investors own include Humana (HUM), American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR), DiamondRock Hospitality (DRH) and AUO (AUOTY). Company Calendar Last Earnings8/03/2026Today9/24/2026Next Earnings (Estimated)11/02/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (12m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 KRYS's financial health is in the Green zone, according to TradeSmith. KRYS has been in this zone for over 12 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:KRYS CIK1711279 Webwww.krystalbio.com Phone(412) 586-5830FaxN/AEmployees295Year Founded2017Price Target and Rating Average Price Target for Krystal Biotech$377.20 High Price Target$474.00 Low Price Target$284.00 Potential Upside/Downside+11.0%Consensus RatingModerate Buy Rating Score (0-4)2.92 Research Coverage13 Analysts Profitability EPS (Trailing Twelve Months)$7.98 Trailing P/E Ratio42.57 Forward P/E Ratio45.42 P/E GrowthN/ANet Income$204.83 million Net Margins54.82% Pretax Margin51.45% Return on Equity19.34% Return on Assets17.65% Debt Debt-to-Equity RatioN/A Current Ratio8.32 Quick Ratio7.96 Sales & Book Value Annual Sales$389.13 million Price / Sales25.84 Cash Flow$7.06 per share Price / Cash Flow48.13 Book Value$42.06 per share Price / Book8.08Miscellaneous Outstanding Shares29,600,000Free Float25,722,000Market Cap$10.06 billion OptionableOptionable Beta0.54 Social Links (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free Report This page (NASDAQ:KRYS) was last updated on 9/24/2026 by MarketBeat.com Staff. From Our PartnersWhy I believe the AI market will split in Q4Matt McCall, who recommended Nvidia near $6 a share, says the AI market is splitting in two - just like the do...The Oxford Club | SponsoredIf you keep cash in a U.S. bank account… read this NOWSince 2020, U.S. banks have been required to keep zero percent of deposits on hand, lending out nearly every d...Banyan Hill Publishing | SponsoredWall Street Legend: “I've discovered a fatal flaw built into Elon's AI model”Wall Street veteran Marc Chaikin says he's found a fatal flaw built into Elon Musk's AI model and every fronti...Chaikin Analytics | SponsoredShocking new footage just releasedGerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...Digest Publishing | SponsoredCongress Passes Landmark Digital Asset Law Wall Street Is WatchingThe House passed the Digital Asset Market Clarity Act 294 to 134, creating the most comprehensive financial te...Awesomely | SponsoredTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...Behind the Markets | SponsoredHow to get a stake in Anthropic — before the IPOAnthropic, the maker of Claude AI, has reportedly filed for an IPO that could arrive as early as October. Its ...Weiss Ratings | SponsoredThis free guide explains options the way they should be taughtMost options educators jump straight into Greeks, spreads, and implied volatility - losing beginners before th...Base Camp Trading | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Krystal Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Krystal Biotech With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
